Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lobaplatin in the preparation of drugs for treating prostate cancer

A technology of prostate cancer and lobaplatin, which is applied in the field of new uses of chemical drugs, can solve the problems of patent literature and research reports that have no treatment effect on prostate cancer

Active Publication Date: 2016-03-09
GUIZHOU YIBAI PHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although previous studies have shown that lobaplatin can be used to prepare and treat various diseases such as breast cancer and small cell lung cancer, there are no patent documents and research reports on the therapeutic effect of lobaplatin and its preparations on prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lobaplatin in the preparation of drugs for treating prostate cancer
  • Application of lobaplatin in the preparation of drugs for treating prostate cancer
  • Application of lobaplatin in the preparation of drugs for treating prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1, the in vitro anti-prostate cancer cell activity of lobaplatin

[0014] 1.1 Materials and reagents:

[0015] 1.1.1 Drug name and batch number: lobaplatin is white freeze-dried powder, batch number 20070501; carboplatin is white powder, batch number 20060703; cisplatin is yellow powder, batch number 36-014050704. Docetaxel, white powder, lot number 268070506; paclitaxel, white powder, lot number 030902; vinorelbine, lot number 080504.

[0016] Provider: Lobaplatin is provided by Hainan Changan International Pharmaceutical Co., Ltd.; carboplatin is the product of Kunming Guiyan Pharmaceutical Co., Ltd.; cisplatin and vinorelbine are products of Jiangsu Hansoh Pharmaceutical Co., Ltd.; docetaxel and paclitaxel are the products of Products of Jiangsu Hengrui Pharmaceutical Co., Ltd.

[0017] Preparation method: the above drugs are formulated with corresponding concentrations in serum-free medium.

[0018] 1.1.2 Cell lines

[0019] PC-3, DU145, LNCAP: human pro...

experiment example 2

[0035] Experimental example 2. Study on the curative effect of lobaplatin on human prostate cancer in vivo

[0036] 2.1 Materials and reagents:

[0037] 2.1.1 Drug name and batch number:

[0038] Lobaplatin: white powder, produced by Hainan Changan International Pharmaceutical Co., Ltd., batch number 20070501;

[0039] Carboplatin: white powder, purchased from Kunming Guiyan Pharmaceutical Co., Ltd., batch number 20060703;

[0040] Cisplatin: yellow powder, purchased from Jiangsu Hansoh Pharmaceutical Co., Ltd., batch number 36-014050704.

[0041] All of the above are raw materials.

[0042] 2.1.2 Preparation method: Lobaplatin, carboplatin, and cisplatin were prepared with 5% GS to the corresponding concentration.

[0043] 2.1.3 Experimental animals

[0044] Male BALB / cA-nude nude mice, 6-7 weeks old, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Certificate number: SCXK (Shanghai) 2003-0003. Breeding environment: SPF grade.

[0045] 2.2 Test method...

experiment example 3

[0063] Experimental Example 3. Clinical trial of lobaplatin and cisplatin in the treatment of non-hormone-dependent prostate cancer

[0064] 3.1 Clinical data: A total of 320 cases were observed, aged 40-75 years. All cases were diagnosed by imaging and confirmed as prostate cancer by prostate cancer puncture pathology; after anti-androgen treatment, it decreased significantly, and then gradually increased; The hematopoietic function of the bone marrow is not significantly damaged, and the liver and kidney functions are basically normal; he has not received radiation therapy, paclitaxel chemotherapy or other treatments within 6 months, and the expected survival time is more than 3 months. There were 242 cases in the lobaplatin group and 78 cases in the cisplatin group.

[0065] 3.2 Experimental drugs:

[0066] Lobaplatin 1: Lobaplatin API, produced by Hainan Changan International Pharmaceutical Co., Ltd., batch number 20080503;

[0067] Lobaplatin 2: prepared according to th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the application of lobaplatin in the preparation of drugs for treating prostate cancer, especially the application in the preparation of drugs for treating non-hormone-dependent prostate cancer. The effective therapeutic dose of lobaplatin is 20-50 mg / m2 body surface area. The present invention It provides new therapeutic drugs for prostate cancer and expands the clinical application of lobaplatin and its preparations.

Description

technical field [0001] The invention relates to the application of lobaplatin in the preparation and treatment of prostate cancer, and belongs to the field of new application of chemical medicines. Background technique [0002] Prostate cancer is a malignant tumor that occurs in male prostate tissue and is the result of abnormal and disordered growth of prostate acinar cells. Prostate cancer incidence varies markedly by geographic and ethnic origin. In developed countries and regions such as Europe and the United States, it is the most common malignant tumor in men, and its mortality rate ranks second among various cancers; in Asia, its incidence rate is lower than that in Western countries, but it has shown a rapid upward trend in recent years. The etiology of prostate cancer has not yet been ascertained, and it may be related to various factors such as heredity, environment, and sex hormones. The secretory function of the prostate is regulated by the androgen testosteron...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/282A61P35/00
Inventor 窦啟玲王平隋东虎冯志刚
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com